Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. - Wikidata - awgldk - TriplyDB

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

http://www.wikidata.org/entity/Q35403688

about

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Cancer immunotherapy: moving beyond current vaccines Serological identification and expression analysis of gastric cancer-associated genes Challenges to the development of antigen-specific breast cancer vaccines.The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response Oncogenomics and the development of new cancer therapies A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy Cancer/testis antigens, gametogenesis and cancer Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.Proteomics in cancer vaccine development.Serological identification of adult T-cell leukaemia-associated antigens.Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma.Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries.Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy Clinical applications of a peptide-based vaccine for glioblastoma.Ovarian cancer immunotherapy: opportunities, progresses and challenges Advanced malignant melanoma: immunologic and multimodal therapeutic strategies EGFRvIII-targeted vaccination therapy of malignant glioma.HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response.Oxidative stress and DNA methylation in prostate cancer.Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer.CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.Defined synthetic vaccines.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.Immunotherapy of melanoma.

P2860

Q24531314-954C6A66-6DBA-4ED4-9764-76F85725E228 Q24548229-65E224E5-9799-4638-BCF1-AC8F98FC72D2 Q24642763-C6F34054-998C-4AC2-ACFB-5FE3C96056BA Q24793404-12462E9D-89C9-4C14-9A9F-C5A2B8066C3F Q28204616-0D648430-4005-4A02-9249-DC486210A34C Q28215652-C524631D-1775-4096-AFEF-20B40F630295 Q28216625-05CECAC8-DFD4-42C0-B691-CE853B00E6A9 Q28251022-90A15D3E-A3ED-4414-A9FA-C866E83A311A Q28263634-A2F07701-6CA4-4367-B887-0445E2136987 Q28709361-77F197E6-2029-4D1B-9ADD-BE61C842D7FE Q29616129-ECCAF835-313C-4145-B198-055A5FBB543B Q30358114-AB7D2C1A-6B9D-43F6-AB72-C1782CFFE8F9 Q30769959-22307B81-DAB1-422F-B20F-CBFD5EEED49C Q30785776-1A6E7587-DB79-466A-8EB8-C25018E8A97D Q33212678-5B716E61-5DA3-41BB-8F12-E207A0ABB394 Q33215044-6ACD4AA7-D760-4727-9BF2-2502E846B276 Q33220307-61F3FAD8-3E83-46C3-8A1C-83A8B3C09408 Q33220308-B27757D1-CA07-430E-8DAB-10C13FE802A7 Q33379115-948737D4-65F6-450E-8B38-387976B676E9 Q33494714-155A4CB4-249E-46B7-80E6-4DBC76E3C8BC Q33522281-CCCDD315-2426-455D-8F7C-B33BD14C4560 Q33668575-42A89AE3-49A0-489A-ADDE-8CA2667D3E1D Q33702218-1EC6196E-90E1-4AFF-9311-77DC83557641 Q33717891-92231787-36AA-4573-AE05-A31984887B90 Q33758459-6320418E-2821-4473-A513-0195D81D0DAD Q33909892-7A3116E8-CDF0-42A3-B6B0-C229BE2BAD27 Q33917224-4B03019F-B55E-4D8D-9885-227DA732CFF7 Q33953046-4E0A1E86-4185-498C-8D6F-5C4DBB496AA0 Q34021985-A92EA2A3-DC01-48BA-8E4B-499B391520FD Q34060255-FDD96284-B61C-45D4-8B76-7D35918FC8B7 Q34111719-17610985-7B76-4682-A523-8E3FCECFFE39 Q34111725-33ECEAD1-92B2-4EB2-B76A-035C39FC8FEE Q34111757-263DD223-C341-42A7-B19C-5A5A63DB5ADE Q34119630-4FFC94C5-1C1E-4A67-BEA5-45E40D678600 Q34154427-060385E8-8212-4794-A6C1-2446691BB152 Q34182308-6403AA5D-CE4F-49A5-A9D1-6D1AC888641A Q34221846-4E8D79E9-1E68-430B-9376-A6752CC3C8D1 Q34280941-E4B3AFDF-CC6B-4329-96F3-F90085A4629E Q34333155-B2C51A9B-FA95-4939-9314-B65F95F05AF4 Q34383950-957E8A56-4A5E-4151-8135-F9CCB8F19B2F

P2860

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

http://www.wikidata.org/entity/Q35403688

description

2000 nî lūn-bûn

@nan

2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@ast

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@en

type

label

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@ast

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@en

prefLabel

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@ast

Induction of primary NY-ESO-1 ...... tients with NY-ESO-1+ cancers.

@en

P1433

Q35403688-85619CCF-9D12-4FDF-9574-E4DAC5E21FBD

P1476

Q35403688-39CE7ACD-A7FA-4D2E-B88F-858C8D59CCF0

P2093

Q35403688-345590B9-8064-4252-8049-CD7661644EA3

Q35403688-4F31F5A8-B01C-441A-80BE-221D13C18FE3

Q35403688-50715390-6B20-4914-92C4-044401DAF5C6

Q35403688-6E8FB0CD-1D1B-4FA9-A885-243E2ED5C331

Q35403688-6F392C71-E564-40A4-95F6-09C02C600E37

Q35403688-7A976B8C-4735-4BC5-849D-7EEB56413897

Q35403688-918F3A8A-AD10-41EA-B9AA-C72E0CD1BE24

Q35403688-A3F3802B-78B1-4686-B356-FA2FF3253008

Q35403688-A66934DE-38FC-4964-A8E1-A69E782E3ACB

Q35403688-ABB7A7FF-4F42-48A6-941F-2D14064A8F36

P2860

Q35403688-00BDD48F-55C1-497E-B990-996E6FB2F886

Q35403688-0265198B-195D-41AC-B743-1E039E4D2DEF

Q35403688-0B6FFD5A-9413-4D43-B09A-1DEC33F30985

Q35403688-177D1D59-870B-4914-8EA9-7CB24061515A

Q35403688-19B33726-E141-44DA-BA5D-B3FF7226A187

Q35403688-1CDC3811-DE59-48C3-B4BE-E7870DC12AD1

Q35403688-1F8738F4-C27C-4635-A1F3-F713213ED6F9

Q35403688-21FA198F-3CB5-4CA0-9AF1-0C16B0D937BC

Q35403688-2A5533FD-4BF0-4A08-9EBD-68E74F40A6D1

Q35403688-4271B517-C255-4585-BD17-6FF4936336B8

P304

Q35403688-FDF0DBE1-D66D-4CDF-8FCF-9AC2E5A47DA3

P31

Q35403688-0B45BED5-B5A4-4BF1-822D-4029EAF3E756

P356

Q35403688-6535AA4B-DE8D-495E-AE4F-64C15B9CFF61

P407

Q35403688-7755AF21-7DC4-4477-BD19-76C4EC2F4144

P433

Q35403688-5FC05B04-177F-4031-A2CB-A5A19D11D6AA

P478

Q35403688-E68653BE-1113-44BD-9F5C-9F6A515517B4

P50

Q35403688-EDAD917F-BF53-4C41-A880-D46F64786B83

P577

Q35403688-30A05A21-722D-4029-9ED7-DC27952B2CA9

P5875

Q35403688-D5C51C7D-1090-4442-8E88-CCB54C313354

P698

Q35403688-E41387BF-A40F-4234-9821-DD06E7DB4DCA

P921

Q35403688-6DD0B442-ECB0-4F1C-9C21-D636998AD9E6

P932

Q35403688-3492EC3B-791B-48B1-BEC6-AE1E90572D6A

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Induction of primary NY-ESO-1 ...... atients with NY-ESO-1+ cancers

@en

P2093

Chen YT

http://www.w3.org/2001/XMLSchema#string

Gnjatic S

http://www.w3.org/2001/XMLSchema#string

Hoffman E

http://www.w3.org/2001/XMLSchema#string

Jäger D

http://www.w3.org/2001/XMLSchema#string

Jäger E

http://www.w3.org/2001/XMLSchema#string

Karbach J

http://www.w3.org/2001/XMLSchema#string

Knuth A

http://www.w3.org/2001/XMLSchema#string

Nagata Y

http://www.w3.org/2001/XMLSchema#string

Neumann A

http://www.w3.org/2001/XMLSchema#string

Old LJ

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Human tumor antigens recognized by T lymphocytes

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

A new era for cancer immunotherapy based on the genes that encode cancer antigens

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.

P304

12198-12203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.220413497

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12297687

http://www.w3.org/2001/XMLSchema#string

P698

11027314

http://www.w3.org/2001/XMLSchema#string

P921

P932

17318

http://www.w3.org/2001/XMLSchema#string